drugset / Trial / NCT02892409
TAK-438 Bismuth Drug Interaction Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety, tolerability, and pharmacokinetics (PK) of quadruple therapy with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and lansoprazole.
Timeline
- Start
- 2016-09-05
- Primary completion
- 2017-04-17
- Completion
- 2017-05-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lansoprazole | Other / unclassified | 30 mg | Oral |
| Subject | Vonoprazan | Other / unclassified | 20 mg | Oral |
| Background | Amoxicillin | Other / unclassified | 1000 mg | Oral |
| Background | Clarithromycin | Small molecule | 500 mg | Oral |
| Background | Tripotassium bismuth dicitrate | Unknown | 600 mg | Oral |